Search
Search
mobile logo
Search

Publications and Presentations

International Liver Cancer (ILCA) 2026 Annual Conference: Younger Age and Clinical Outcomes in Patients with Unresectable Hepatocellular Carcinoma Treated with Camrelizumab +
Rivoceranib vs Sorafenib (CARES-310)

ASCPT 2026: The Mass Balance and Metabolic Profile of Lirafugratinib in Healthy Male VolunteersComparative Biochemical Kinase Activity Analysis Identifies Lirafugratinib as a Highly Selective FGFR2 Inhibitor

AACR 2026: Comparative Biochemical Kinase Activity Analysis Identifies Lirafugratinib as a Highly Selective FGFR2 Inhibitor

2026 ASCO® Annual Meeting: A Phase 2, open-label, single-arm study of lirafugratinib in patients with previously treated, unresectable, locally advanced, or metastatic solid tumors (excluding cholangiocarcinoma) with FGFR2 fusion or rearrangement

2026 AACR® Annual Meeting: Comparative Biochemical Kinase Activity Analysis Identifies Lirafugratinib as a Highly Selective FGFR2 Inhibitor

2026 ASCO® GI Annual Meeting: Efficacy and safety of lirafugratinib in patients with FGFRi-naïve cholangiocarcinoma harboring FGFR2 fusions/rearrangements

ASCO GI 2025: Clinical outcomes of camrelizumab + rivoceranib vs sorafenib (CARES-310) as first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC) of viral and non-viral etiology

2025 ESMO® Annual Meeting: CARES-310 – Clinical benefit of camrelizumab + rivoceranib in unresectable hepatocellular carcinoma patients with macrovascular invastion and extrahepatic spread

2025 ESMO® GI Annual Meeting: Cares-310 – Association of alpha-fetoprotein (AFP) and clinical outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with camrelizumab + rivoceranib vs sorafenib

ESMO 2024: A Phase 1 Study of Rivoceranib Combined with Nivolumab in Patients with Unresectable or Metastatic Cancer

AACR 2024: Effect of Rivoceranib Administered as 200 mg Once Daily on the Pharmacokinetics of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 Substrates

ESMO 2024: Analysis of Antidrug Antibodies (ADA) to Camrelizumab in CARES-310: The Pivotal Phase 3 Study of Camrelizumab + Rivoceranib in Unresectable Hepatocellular Carcinoma (uHCC)

ESMO 2024: Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis to Assess the Impact of Treatment With Camrelizumab + Rivoceranib (cam+rivo)
on Quality of Life vs Sorafenib in Patients With Unresectable Hepatocellular Carcinoma: Study CARES-310

52nd Annual Meeting of Korean Cancer Association: Post hoc analysis of efficacy and safety between US and Korean patients treated with rivoceranib for recurrent or metastatic adenoid cystic carcinoma

Cancer Research and Treatment: Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors 

Gastric Cancer: Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial

Liver Cancer: Impact of age on patient-reported outcomes with first-line camrelizumab plus rivoceranib versus sorafenib in adults with unresectable hepatocellular carcinoma: Post hoc analyses of the CARES-310 open-label, randomized, phase 3 trial

Clinical Pharmacokinetics: Effect of Rivoceranib 200 mg Once Daily on the Pharmacokinetics of a Cocktail Probe Substrate of Cytochrome P450 Enzymes: A Phase I Trial in Healthy Volunteers

2024 ASCO® Annual Meeting: Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study

Role of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte-ratio (PLR) in unresectable hepatocellular carcinoma (uHCC): Subgroup analysis of patients treated with camrelizumab (cam) + rivoceranib (rivo) in the CARES-310 trial.

The Lancet 2023: Camrelizumab Plus Rivoceranib Versus Sorafenib as First-Line Therapy for Unresectable Hepatocellular Carcinoma (CARES-310): a Randomised, Open-Label, International Phase 3 Study

2024 ASCO® Gastrointestinal Cancers Symposium: Patient-Reported Outcomes (PROs) <65 or ≥65 Years Old From CARES-310 Camrelizumab + Rivoceranib vs Sorafenib as First-Line Treatment for Patients With Unresectable Hepatocellular Carcinoma

2024 ASCO® Gastrointestinal Cancers Symposium: Impact of Baseline Liver Function on Survival Outcomes in Patients With Unresectable Hepatocellular Carcinoma (uHCC) Treated With Camrelizumab + Rivoceranib vs Sorafenib: A Post Hoc Analysis of Study CARES-310

ESMO 2023: Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Rivoceranib Plus Trifluridine/Tipiracil in Patients With Previously Treated Metastatic Colorectal Cancer

Clinical Cancer Research 2023: A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

Cancer Chemotherapy and Pharmacology 2023: Comparative Biochemical Kinase Activity Analysis Identifies Rivoceranib as a Highly Selective VEGFR2 Inhibitor

2023 ASCO® Annual Meeting: Updated Results From a Phase 2 Study of the Oral Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitor Rivoceranib for Recurrent or Metastatic (R/M) Adenoid Cystic Carcinoma (ACC)

2023 ASCO® Annual Meeting: Updated Results From a Phase 2 Study of the Oral Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitor Rivoceranib for Recurrent or Metastatic (R/M) Adenoid Cystic Carcinoma (ACC)

2023 ASCO® Annual Meeting: Phase 1, Randomized, Open-Label, Single-Dose, Crossover Study to Evaluate the Bioequivalence of Four Formulations of Oral Rivoceranib Tablets in Healthy Subjects

AACR 2023: Comparative Biochemical Kinase Activity Analysis Identifies Rivoceranib as a Highly Selective VEGFR-2 Inhibitor

AACR 2023: Effect of Rivoceranib on the Pharmacokinetics of Cytochrome P450 Enzyme Substrates: A Phase 1 Trial in Healthy Volunteers

ESMO 2022: Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Rivoceranib Plus Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer

2022 ASCO® Annual Meeting: A Phase 2 Study of the Oral Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitor, Rivoceranib, for Recurrent or Metastatic (R/M) Adenoid Cystic Carcinoma (ACC)

Gynecologic Oncology: Phase 3 Publication of Efficacy & Safety Results Comparing Paclitaxel Micellar & Cremophor EL-Paclitaxel

2020 ASCO® Annual Meeting: A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of Rivoceranib in Recurrent or Metastatic Adenoid Cystic Carcinoma

2019 ASCO®-SITC Clinical Immuno-Oncology Symposium: Phase I Study to Evaluate the Safety and Efficacy of Rivoceranib (Apatinib) and Nivolumab in Patients with Unresectable or Metastatic Cancer

AACR 2018: Synergistic Tumor-Suppressive Effect of Apatinib (Rivoceranib), a Selective VEGFR-2 Inhibitor, in Combination With Immunotherapy in a Syngeneic Murine Lung Cancer Model

ACCP 2017: A Phase I Study to Evaluate the Pharmacokinetics of a Single Dose of Apatinib Mesylate (YN968D1) Tablets in Healthy Male Caucasian, Japanese, and Chinese Subjects

2017 ASCO® Annual Meeting: A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Apatinib Plus Best Supportive Care (BSC) Compared to Placebo Plus BSC in Patients With Advanced or Metastatic Gastric Cancer: The ANGEL Study

ESMO 2016: A Phase II Study of Apatinib, a Highly Selective Inhibitor of VEGFR-2, in Patients With Metastatic Solid Tumors Without Standard Treatment Options

Stay connected